SB415286

CHF 50.00
In stock
AG-CR1-3658-M0011 mgCHF 50.00
AG-CR1-3658-M0055 mgCHF 120.00
AG-CR1-3658-M02525 mgCHF 490.00
More Information
Product Details
Synonyms 3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione
Product Type Chemical
Properties
Formula

C16H10ClN3O5

MW 359.7
CAS 264218-23-7
Purity Chemicals ≥97%
Appearance Yellow solid.
Solubility Soluble in DMSO (10mg/ml), ethanol (5mg/ml) or methanol.
InChi Key PQCXVIPXISBFPN-UHFFFAOYSA-N
Smiles ClC1=CC(NC2=C(C3=C([N+]([O-])=O)C=CC=C3)C(NC2=O)=O)=CC=C1O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent and selective cell permeable, ATP-competitive inhibitor of GSK3α with an IC50 value of 78nM (and similar potency for GSK3β).
  • DYRK1A inhibitor (IC50=0.9µM).
  • Stimulates glycogen synthesis in liver cells and induces β-catenin-dependent gene transcription.
  • Acts as neuroprotectant and prevents neuronal cell death induced by PI3-kinase pathway.
  • Anticancer agent with antiproliferative activity.
  • Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase that is inhibited by an assortment of extracellular stimuli such as insulin, growth factors, cell specification factors and cell adhesion. Its activity regulates many cell functions including the control of cell division, apoptosis and inflammation.
Product References
  1. Selective small molecule inhibitors or glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription: M.P. Coghlan, et al.; Chem. & Biol. 7, 793 (2000)
  2. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death: D.A.E. Cross, et al.; J. Neurochem. 77, 94 (2001)
  3. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase: K. MacAulay, et al.; Eur. J. Biochem. 270, 3829 (2003)
  4. GSK3 inhibitors: development and therapeutic potential: P. Cohen & M. Goedert; Nat. Rev. Drug Discov. 3, 479 (2004)
  5. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta: B.J.R. Whittle, et al.; Br. J. Pharmacol. 147, 575 (2006)
  6. The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)
  7. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS: J. Dill, et al.; J. Neurosci. 28, 8914 (2008)
  8. A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286: J.G. Pizarro, et al.; J. Cell. Mol. Med. 13, 3906 (2009)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.